Clorox Co stock (US1890541097): new Clorox Healthcare wipes launch adds product momentum after recent guidance update

Clorox Co shares on the New York Stock Exchange traded broadly in line with the wider U.S. consumer staples space as the company highlighted new Clorox Healthcare disinfecting wipes while investors continued to weigh its latest full-year 2026 earnings guidance.

Clorox Co, the U.S.-based consumer staples group listed on the New York Stock Exchange under the ticker CLX, saw its stock trade in line with broader household products peers on 06/02/2026 as the company spotlighted a fresh product push in its Clorox Healthcare division and investors continued to digest its most recent full-year 2026 earnings guidance.

According to NYSE price data referenced by MarketBeat as of 06/02/2026, Clorox shares opened the Tuesday session at around USD 89, placing the stock in the lower half of its 12-month trading range as U.S. consumer staples valuations adjust to slower volume growth and higher funding costs.

The stock is part of the U.S. consumer staples segment and is primarily followed by investors through its New York listing, although the shares are also available to German retail investors via off-exchange venues such as Tradegate where they are quoted in euro alongside the U.S.-dollar primary line.

On the operational side, Clorox used an early-June communication from its healthcare-focused unit to underscore innovation in infection prevention products, adding a tangible near-term catalyst for its professional solutions portfolio.

In a 06/02/2026 press release, Clorox Healthcare announced two new disinfecting wipe platforms: Clorox Healthcare Quat Alcohol Disinfecting Wipes and Clorox Healthcare HyperOxi Disinfecting Wipes, both designed to address compliance challenges and surface compatibility issues in medical environments.

The new Quat Alcohol Disinfecting Wipes are described as offering a one-minute contact time while using 40% less alcohol than certain comparable formulations, a combination aimed at keeping surfaces visibly wet for the required dwell time without leaving excessive residue.

The HyperOxi Disinfecting Wipes are positioned as a bleach-free sporicidal option powered by the companys proprietary Quanticare Technology, with the product tested to kill Clostridioides difficile spores in four minutes and to inactivate a range of other key healthcare pathogens in one minute or less.

Both new wipe platforms are planned to be offered in multiple package sizes and are expected to become available to hospitals and other healthcare providers later in 2026 through major distributors, subject to completion of all relevant regulatory clearances.

By highlighting these additions to its healthcare portfolio, Clorox is signaling ongoing product development in professional cleaning solutions at a time when investors are closely watching the mix of consumer retail and institutional revenue streams following the companys cyberattack-related disruption in 2023 and subsequent recovery.

From a guidance standpoint, the company has in parallel reaffirmed a full-year 2026 earnings outlook that implies moderate growth and margin stability compared with the current-year baseline.

Recent filings summarized by MarketBeat indicate that Clorox has set its fiscal year 2026 guidance at earnings per share between USD 5.45 and USD 5.65, framing an internal target band that centers around USD 5.55.

The same MarketBeat overview notes that sell-side analysts currently expect the company to deliver roughly USD 5.61 in earnings per share for the ongoing year, a number that sits near the middle of managements 2026 guidance range and suggests only limited divergence between external forecasts and internal planning assumptions.

On the shareholder front, the stock continues to attract large institutional investors that position the shares as part of a defensive consumer staples allocation.

MarketBeat reported on 06/02/2026 that Nomura Asset Management Co. Ltd. disclosed the purchase of 16,852 Clorox shares, while a separate filing showed National Pension Service acquiring 11,233 shares, both pointing to interest from Asian long-term capital allocators in the U.S. household products name.

These positions underscore that the stock remains actively owned by global asset managers even as its valuation has compressed relative to historical averages amid changing expectations for volume growth and pricing power in North American cleaning and lifestyle categories.

The stock traded at USD 89.10 on 06/02/2026 on the New York Stock Exchange, according to MarketBeat as of 06/02/2026.

In Germany, the stock was also quoted on Tradegate in euro terms on 06/02/2026, offering an additional access point for European private investors who prefer domestic trading venues.

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: CLX
• Sector/industry: Consumer staples - household and personal products
• Headquarters/country: Oakland, United States
• Core markets: United States, with incremental sales in selected international markets
• Key revenue drivers: Branded cleaning products, household care ranges, lifestyle brands and professional cleaning solutions sold mainly through retail and institutional channels
• Home exchange/listing venue: New York Stock Exchange (CLX)
• Trading currency: USD

Clorox Co: core business model

Clorox Co centers its business on developing and marketing branded cleaning, household and lifestyle products along with professional hygiene solutions, generating revenue predominantly from selling these goods to retailers and institutional customers across the United States and select international markets.

Latest quarterly results for Clorox Co at a glance

While the company has not reported a new quarter in June 2026 so far, the latest available earnings cycle and the current guidance framework give investors a sense of how management sees the next financial year evolving.

Based on information collated by MarketBeat from recent company disclosures, Clorox has framed its fiscal year 2026 earnings outlook in a range of USD 5.45 to USD 5.65 per share, a band that brackets the sell-side consensus forecast for the current year, which stands at roughly USD 5.61 per share.

In practice, this implies that management expects modest earnings progress through a combination of cost controls, productivity initiatives and a gradually normalizing gross margin profile, with any incremental upside or downside likely driven by volume trends in core cleaning brands and by the pace at which institutional and professional demand develops in areas such as Clorox Healthcare.

The latest results commentary from company and third-party sources has emphasized profitability improvement relative to earlier periods, with Built In highlighting that Cloroxs recent fiscal year showed rising net income and better margins, supported by efficiency gains and restructuring benefits that management is seeking to carry into upcoming reporting periods.

Conclusion

The combination of new Clorox Healthcare disinfecting wipes and a clearly communicated fiscal 2026 earnings guidance range provides investors with both a tactical product story and a strategic profitability framework for Clorox Co.

With the stock trading around USD 89 on the New York Stock Exchange and institutional investors such as Nomura Asset Management and National Pension Service adding exposure, market participants are weighing how innovation in professional hygiene products and ongoing cost initiatives will translate into earnings delivery over the next reporting cycles.

Against a backdrop of recalibrated consumer staples valuations in the United States, the companys ability to balance volume trends in its core household brands with growth in healthcare and professional channels will likely remain central to how the shares are priced relative to peers.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.